Fexofenadine HCL Follow On
ID: SPE2D219D0077P00001Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/80c0b3d280fe475bbdb0239639f82d3f/view
Timeline
  1. 1
    Posted Dec 17, 2019, 7:10 PM UTC
  2. 2
    Updated Dec 17, 2019, 7:10 PM UTC
  3. 3
    Due Not available
Description

Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is procuring Fexofenadine HCL Follow On. Fexofenadine HCL is typically used as an antihistamine to relieve allergy symptoms such as watery eyes, runny nose, itching eyes/nose, sneezing, hives, and itching.

Point(s) of Contact
Catherine Gilbert
(215) 737-4778
catherine.gilbert@dla.mil
Denise Taubman
(215) 737-8677
denise.taubman@dla.mil
Files
Title
Posted
Fexofenadine Mod P00001 - clause change SIGNED.pdf
Mar 28, 2024, 12:20 AM UTC
Lifecycle
Title
Type
Fexofenadine HCL Follow On
Currently viewing
Special Notice
Similar Opportunities
Fexofenadine HCL Follow On MOD P00002
Buyer not available
Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking Fexofenadine HCL Follow On MOD P00001. Fexofenadine HCL is a drug used to relieve symptoms of seasonal allergies such as runny nose, sneezing, itchy or watery eyes, and itching of the nose or throat. This procurement is for NDC changes. For more information, please contact Catherine Gilbert at catherine.gilbert@dla.mil or 2157374778.
Famotidine
Buyer not available
Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
Fluconazole Tablets
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Fluconazole Tablets, which are essential pharmaceuticals used in various medical treatments. The procurement will include multiple formulations of Fluconazole, specifically 50 MG, 100 MG, 200 MG tablets in various counts, and 150 MG tablets in unit dose packs, aimed at supporting the Department of Defense, Bureau of Prisons, Indian Health Service, and Department of Veterans Affairs. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base and four one-year options, with the solicitation expected to be posted in April 2024. Interested parties should direct inquiries to Courtney Hunter-Stangler at Courtney.Hunter-Stangler@dla.mil and are encouraged to monitor the DLA Bid Board System and SAM.gov for updates.
Fluticasone Propionate
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Fluticasone Propionate, a pharmaceutical product essential for respiratory treatments. The procurement will include various formulations of Fluticasone Propionate combined with Salmeterol, specifically in HFA inhalers, and aims to establish a national supply source for the Department of Defense, Indian Health Service, and Bureau of Prisons customers. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base period and four one-year options, with the solicitation expected to be posted in May 2025. Interested parties can direct inquiries to Jeremy Brown at jeremy.brown@dla.mil or call 445-737-5419, and are encouraged to set up automated notifications for updates on the solicitation.
Valsartan/Hydrochlorothiazide Tablets
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Valsartan/Hydrochlorothiazide Tablets, which includes various dosages in 90 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are essential for treating hypertension and heart failure, and will serve customers including the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in May 2025. Interested parties can reach out to Kyle Lewicki at (215) 737-3696 or kyle.lewicki@dla.mil for inquiries, and are encouraged to monitor the DLA Bid Board System and Sam.Gov for updates.
Solifenacin
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Solifenacin, specifically 5MG and 10MG tablets in 30 and 90 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which will be utilized by the Department of Defense, Indian Health Service, and Bureau of Prisons through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be fully competitive and unrestricted. Interested parties should direct inquiries to Jayne Do at jayne.do@dla.mil, with the solicitation anticipated to be posted in April 2025 on the DLA Bid Board System and SAM.gov.
Duloxetine HCL DR Capsules
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Duloxetine HCL DR Capsules, which includes various dosages and packaging options. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in April 2025. Interested parties should direct inquiries to Christopher Newman at christopher.newman@dla.mil or 445-737-7371, and are encouraged to monitor the DLA Bid Board System and Sam.Gov for updates.
Rizatriptan Benzoate
Buyer not available
Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.
Dextroamphetamine - Amphetamine ER
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Dextroamphetamine - Amphetamine ER Capsules, specifically in dosages of 5 MG, 10 MG, 15 MG, 20 MG, 25 MG, and 30 MG, packaged in 100 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which will be utilized by the Department of Defense, Bureau of Prisons, and Indian Health Service customers through DLA and VA prime vendor programs. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be solicited as a commercial item under FAR part 12. Interested parties should monitor the DLA Bid Board System (DIBBS) and SAM.gov for the solicitation, projected for April 2025, and can direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil.
Fluconazole - Modification P00005 to Contract
Buyer not available
Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY - TROOP SUPPORT MEDICAL is seeking a modification to the contract for Fluconazole. Fluconazole is a medication used to treat and prevent fungal infections. The modification, P00005, will involve changing the National Drug Codes (NDCs) associated with the procurement.